SciClone Pharmaceuticals About
SciClone Pharmaceutical SciClone is a pharmaceutical company
engaged in developing and commercialization of therapeutic drugs to treat life-threatening
ilnesses. SciClone’s primary objective is to develop its lead compound ZADAXIN®
for the treatment of hepatitis C, hepatitis B and certain cancers. PRODUCT
PIPELINE CHART --PRODUCT DEVELOPMENT ZADAXIN® -- proposed
machanism --facilitates the body’s immune response to fight viruses and certain
cancers. The compound is a synthetic version of the naturally occurring peptide
thymosin alpha 1, generically referred to as thymalfasin. ZADAXIN increases the
production of white blood cells, such as T-cells. SCV-07 -- is a
synthetic dipeptide that has demonstrated immunomodulatory activity by increasing
T-cell differentiation and function.